Posted by Michael Wonder on 12 Nov 2020
ICER releases draft evidence report on treatments for high cholesterol
12 November 2020 - Public comment period on preliminary draft now open until 11 December 2020; requests to make oral comment during public meeting also being accepted.
The Institute for Clinical and Economic Review today released a Draft Evidence Report assessing the comparative clinical effectiveness and value of inclisiran (Novartis), bempedoic acid (Nexletol, Esperion Therapeutics), and bempedoic acid/ezetimibe (Nexlizet, Esperion Therapeutics) for patients with heterozygous familial hypercholesterolaemia and for secondary prevention of ASCVD.
